Abstract |
This review encompasses relevant scientific and clinical advances in atopic dermatitis (AD) published in 2017. These include articles from the Journal of Allergy and Clinical Immunology, as well as other prominent publications that have contributed to the emerging field, on the microenvironment of the skin and molecular patterns guiding biologic treatment strategies. The most commonly questioned and explored themes of the year included the effect of the microbiome on AD development, as well as cell signaling and symptom severity. Topics also included the description of patient-specific molecular endotypes within the larger population with AD. All of these factors will create potential opportunities to guide personalized therapy with the broadening array of topical and systemic interventions currently available, as well as providing new insights to guide the development of novel molecularly targeted therapeutics. With recent US Food and Drug Administration approval of the first wave of new targeted therapies for AD, additional information exploring the safety profiles and long-term effects of these medications was also at the forefront in 2017.
|
Authors | Katie Kennedy, Jennifer Heimall, Jonathan M Spergel |
Journal | The Journal of allergy and clinical immunology
(J Allergy Clin Immunol)
Vol. 142
Issue 6
Pg. 1740-1747
(Dec 2018)
ISSN: 1097-6825 [Electronic] United States |
PMID | 30359683
(Publication Type: Journal Article, Review)
|
Copyright | Copyright © 2018 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved. |
Chemical References |
- Biological Products
- Cytokines
|
Topics |
- Animals
- Biological Products
(therapeutic use)
- Cytokines
(immunology)
- Dermatitis, Atopic
(immunology, microbiology, therapy)
- Humans
- Microbiota
- Skin
(immunology, microbiology)
|